These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Jung G; Breuer J; Poll LW; Koch JA; Balzer T; Chang S; Mödder U Acta Radiol; 2006 Feb; 47(1):15-23. PubMed ID: 16498928 [TBL] [Abstract][Full Text] [Related]
26. Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient. Hammerstingl R; Zangos S; Schwarz W; Rosen T; Bechstein WO; Balzer T; Vogl TJ Acad Radiol; 2002 May; 9 Suppl 1():S119-20. PubMed ID: 12019845 [No Abstract] [Full Text] [Related]
27. Effect of change in transporter expression on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging during hepatocarcinogenesis in rats. Tsuda N; Harada K; Matsui O J Gastroenterol Hepatol; 2011 Mar; 26(3):568-76. PubMed ID: 21332553 [TBL] [Abstract][Full Text] [Related]
28. Correction to The Dixon technique and the frequency-selective fat suppression technique in three-dimensional T1 weighted MRI of the liver: a comparison of contrast-to-noise ratios of hepatocellular carcinomas-to-liver. Br J Radiol; 2016 Oct; 89(1066):20150117e. PubMed ID: 27572243 [No Abstract] [Full Text] [Related]
35. Assessing antiangiogenic therapy response by DCE-MRI: development of a physiology driven multi-compartment model using population pharmacometrics. Steingoetter A; Menne D; Braren RF PLoS One; 2011; 6(10):e26366. PubMed ID: 22028864 [TBL] [Abstract][Full Text] [Related]
36. Breath-hold spin-echo MR imaging for evaluation of dynamic enhancement of native and treated hepatocellular carcinoma after intravenous Gd-DTPA administration. Lencioni R; Mascalchi M; Paolicchi A; Zampa V MAGMA; 1995; 3(3-4):151-6. PubMed ID: 8749733 [TBL] [Abstract][Full Text] [Related]
37. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Kudo M Oncology; 2010 Jul; 78 Suppl 1():87-93. PubMed ID: 20616589 [TBL] [Abstract][Full Text] [Related]
38. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. Jia J; Puls D; Oswald S; Jedlitschky G; Kühn JP; Weitschies W; Hosten N; Siegmund W; Keiser M Invest Radiol; 2014 Feb; 49(2):78-86. PubMed ID: 24056116 [TBL] [Abstract][Full Text] [Related]
39. Double contrast MR imaging of hepatocellular carcinoma evaluating lesion detection and conspicuity. Akinci D; Oto A; Besim A; Akhan O; Abbasoglu O; Batman F; Eryilmaz M Acad Radiol; 2002 Aug; 9 Suppl 2():S466-7. PubMed ID: 12188310 [No Abstract] [Full Text] [Related]
40. Will CT take second billing to MR imaging for the diagnosis of hypervascular hepatocellular carcinomas hereafter? Kanematsu M Radiology; 2011 Aug; 260(2):607; author reply 607-8. PubMed ID: 21778455 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]